Honolulu, Hawaii – (October 29th, 2008) CBI Polymers, a division of Cellular Bioengineering Inc. (CBI), announced today the launch of its DeconGel™ 1101 product. DeconGel™ is the most effective radiological decontamination solution available to industries worldwide ranging from nuclear power utilities, decommissioning and decontamination sites, hospital facilities, and research laboratories. The worldwide market is estimated to be $200 million per year.
DeconGel™ effectively decontaminates a broad range of surfaces and contaminants. Its extraordinary binding properties allow it to trap and encapsulate a wide spectrum of radioisotopes on different substrates in a simple, no-preparation process allowing easy and safe disposal without the use of water or cleaning agents.
DeconGel™ has been in beta testing for the past year, and has secured more than 30 customers around the world. Current customers include Ontario Power Generation, Washington Savannah River Company, Sandia National Laboratory, Lawrence Livermore National Laboratory, Colorado State University, and Tripler Army Medical Center.
DeconGel™’s advantages and innovations include:
- Immediate fixation of the contamination
- Safe and user friendly
- Cost effective (significantly reduces staff hours spent performing the decontamination procedure)
- Easy application, removal, and disposal
- Environmental friendly, no waste water and a minimal amount of solid waste generated
“DeconGel™ is an amazing contribution to our industry. We especially like how easy and efficient DeconGel™ is to use,” stated Dan Young, First Line Manager at Ontario Power Generation, “We used the gel to decontaminate a concrete room that was difficult to clean with our current method. The application was very simple. We applied the gel and peeled the next day. It came up from the floor very easily with minimal waste generated and reduced the loose contamination from 5000 cpm (counts per minute) to 0 cpm.”
“Using DeconGel™ resulted in substantial cost savings for our department,” said Tom Johnson, PhD., Assistant Professor in the Department of Environmental and Radiological Health at Colorado State University, “We utilized DeconGel™ to effectively decontaminate volatized tritiated thymadine from one of our chemical hoods. This resulted in CSU being able to begin using the hood facility after four years of not being able to use it.”
“The transformation of novel ideas to commercial products is the hallmark of CBI, and we believe DeconGel™ will play a critical role in the management of radiological and nuclear contamination on a global scale,” says Roberto Mandanas, General Manager of DeconGel™. “We plan to enter into strategic alliance with major industry partners in key world markets in the coming months.”
DeconGel™ was initially funded by the Hawaii Technology Development Venture (HTDV) under its contract with the Office of Naval Research (ONR). Additional R&D funding was secured through the USAF Force Protection Battlelab, HTDV, and the National Defense Center of Excellence for Research in Ocean Sciences (CEROS) under its contract with the Defense Advanced Research Projects Agency (DARPA).
For information regarding DeconGel™, go to www.decongel.com, or contact Roberto Mandanas at rmandanas@cellularbioengineering.com.
About CBI
CBI invents, develops, and acquires disruptive technologies to transform novel ideas and innovations to commercial products. The Company has an Intellectual Property portfolio of over 25 patents and patent applications, and four operating divisions including:
- DeconGel™ is a commercialized product with superior efficacy for the containment and decontamination of radioactive and nuclear spills, and with additional applications in industrial cleaning and environmental management.
- Eyegenix™ is a bio-integrating artificial cornea. It is in pilot human clinical trials, and holds the promise of returning sight to 10 million people worldwide who are blind from corneal disease.
- PixiTag™ is a nanoporous silica microtag which can be used to authenticate valuable assets, from great works of art and luxury goods to pills and capsules to be ingested, protecting consumers from loss and the health risks of counterfeit products.
- E Canary is a bio-sensor comprised of living cardiac cells on a CCD chip which can detect both known and unknown harmful threats in the environment such as chemical contaminants and biologic weapons.
Please go to www.cellularbioengineering.com for further information.
Media Contact:
Linda Jameson
(808) 221-3552
ljameson821@gmail.com
No comments:
Post a Comment